Guard Therapeutics International AB (publ) (“Guard Therapeutics” or the “Company”) today announced that the number of shares and votes in the Company has changed due to the recently completed Rights Issue (for further information, see the Company’s press release on April 4, 2025).
Through the Rights Issue, the number of shares and votes increased by 7,872,753 shares, amounting to a total of 20,167,631 shares and votes in Guard Therapeutics. External investors who had undertaken to guarantee the Rights Issue chose to receive the guarantee commission in cash.